34 patents
Page 2 of 2
Utility
Site-specific Enzymes and Methods of Use
4 Mar 21
The present invention provides polypeptides related t Ralstonia proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
Eric M. OSTERTAG, Tseten YESHI
Filed: 16 Nov 20
Utility
Site-specific enzymes and methods of use
23 Nov 20
The present invention provides polypeptides related to Ralstonia proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
Eric M. Ostertag, Tseten Yeshi
Filed: 21 Jul 19
Utility
Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization for Tumors
28 Oct 20
Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM, leading to widespread shutdown of vascular flow, hemorrhage, and necrosis.
P. Peter GHOROGHCHIAN
Filed: 9 Jul 20
Utility
Site-specific Enzymes and Methods of Use
24 Jun 20
The present invention provides polypeptides related to Ralstonia proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
Eric M. Ostertag, Tseten Yeshi
Filed: 21 Jul 19
Utility
Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization of Tumors
6 May 20
Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM as a result of the nitric oxide sequestration by PEM.
P. Peter GHOROGHCHIAN
Filed: 5 Nov 19
Utility
Modified Stem Cell Memory T Cells, Methods of Making and Methods of Using Same
6 May 20
The disclosure provides a method of producing modified stem memory T cells (e.g.
Eric M. OSTERTAG, Devon SHEDLOCK
Filed: 28 Oct 19
Utility
Hyperactive Piggybac Transposases
18 Mar 20
The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
Eric M. OSTERTAG, Blair MADISON
Filed: 18 Mar 19
Utility
Compositions and Methods for Selective Elimination and Replacement of Hematopoietic Stem Cells
11 Mar 20
Disclosed are methods of eliminating at least on target cell in a subject, comprising administering to the subject an effective amount of a composition comprising a plurality of immune cells, wherein each immune cell of the plurality expresses one or more chimeric ligand receptor(s) (CLR(s)) that each specifically bind to a target ligand on the at least one target cell, wherein specifically binding of the one or more CLR(s) to the target activates the immune cell, and wherein the activated immune cell induces death of the target cell.
Eric M. OSTERTAG, Devon SHEDLOCK, Julian David DOWN
Filed: 12 Mar 18
Utility
CorrectedTransposon System and Methods of Use
26 Feb 20
Disclosed are methods for the ex-vivo genetic modification of an immune cell comprising delivering to the immune cell, (a) a nucleic acid or amino acid sequence comprising a sequence encoding a transposase enzyme and (b) a recombinant and non-naturally occurring DNA sequence comprising a DNA sequence encoding a transposon.
Devon SHEDLOCK, David HERMANSON, Eric OSTERTAG
Filed: 19 Dec 17
Utility
Compositions and Methods for Improved Encapsulation of Functional Proteins In Polymeric Vesicles
8 Jan 20
Methods of preparing polymersome-encapsulated functional protein suspensions may include thermally blending an amount of a block copolymer with an amount of a low molecular weight polyethylene glycol (PEG) for at least 30 minutes, mixing and cooling a resulting PEG/polymer formulation to room temperature, adding an aliquot of a solution of the functional protein to a sample containing the PEG/polymer formulation, and performing at least three dilution steps in which polymersomes that are generated are progressively saturated with the functional protein.
P. Peter GHOROGHCHIAN, Jivan Namdeo YEWLE
Filed: 19 Sep 19
Utility
Compositions and Methods for Inducing Nanoparticle-mediated Microvascular Embolization for Tumors
1 Jan 20
Nanoparticle mediated microvascular embolization (NME) of tumor tissue may occur after systemic administration of PEM, leading to widespread shutdown of vascular flow, hemorrhage, and necrosis.
P. Peter GHOROGHCHIAN
Filed: 17 Jan 19
Utility
Modified stem cell memory T cells, methods of making and methods of using same
23 Dec 19
The disclosure provides a method of producing modified stem memory T cells (e.g.
Eric Ostertag, Devon Shedlock
Filed: 9 Oct 18
Utility
Chimeric Antigen Receptors (Cars) Specific for MUC1 and Methods for Their Use
30 Oct 19
Disclosed are MUC1-CAR compositions and methods for use of these compositions to target a MUC1 protein, including CARTyrin compositions, wherein the cell expressing the targeted MUC1 protein may be targeted and killed by, for instance, a cytotoxic T cell.
Eric Ostertag, Devon Shedlock
Filed: 16 Jul 17
Utility
Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
28 Oct 19
Methods of preparing polymersome-encapsulated functional protein suspensions may include thermally blending an amount of a block copolymer with an amount of a low molecular weight polyethylene glycol (PEG) for at least 30 minutes, mixing and cooling a resulting PEG/polymer formulation to room temperature, adding an aliquot of a solution of the functional protein to a sample containing the PEG/polymer formulation, and performing at least three dilution steps in which polymersomes that are generated are progressively saturated with the functional protein.
P. Peter Ghoroghchian, Jivan Namdeo Yewle
Filed: 29 Jun 16